新闻

Hisun Pharmaceutical monopolizes the production batch number of piravir: the annual R & D cost exceeds 6 billion

Hisun Pharmaceutical monopolizes the production batch number of piravir: the annual R & D cost exceeds 6 billion
On March 17th, Fapiravir, a drug recommended by the Ministry of Science and Technology to resume alternative treatment programs, received attention. The drug is a broad-spectrum antiviral drug. Currently, Fapiravir is clinically shown to be effective enough to shorten the duration of influenza and reduce viral loadthe amount.  The data shows that only the Zhejiang Haizheng Pharmaceutical Co., Ltd. has the production batch number of the current Fapiravir products, and the approval date is February 15, 2020.In early March, Sihuan Pharmaceutical, a Hong Kong-listed company, also announced that it will start clinical studies of fapiravir tablets for use in new coronavirus diseases.  For Hisun Pharmaceutical, Fapiravi has been on the road of research and development for nearly 4 years.  According to the data, Fapiravir is a broad-spectrum antiviral drug developed by Fuji Corporation of Japan.All have good suppression effect.The results of clinical trials show that fapiravir is effective enough to correct the course of influenza and reduce viral load.  In March 2014, Fapiravir was approved to be marketed in Japan. The indication is for the treatment of new or recurrent influenza in adults (only when other anti-influenza virus drugs are not effective or not effective).Toyama Chemical Industry Co., Ltd. made an initial compound patent application for fapiravir in August 1999, with a term of 20 years. The compound patent expired in August 2019.  As early as June 2016, Hisun Pharmaceutical announced that it had signed a patent licensing contract with Japan’s Fujifilm Co., Ltd. for the anti-influenza virus drug “Avigan tablets”, and Fujifilm Co., Ltd. placed its “Favipiravir” in China.The patents obtained are paid to the company for permission, allowing Hisun Pharmaceutical to use its related patents (including compound patents and use patents) containing “fapiravir” in China (excluding Taiwan, Hong Kong and Macau) for research and development, manufacturing, Sell anti-influenza virus drugs, and pay the company a one-time fee and royalties after the sale starts.  In the agreement at the time, the royalties of the above patented products did not exceed 7% of the final product sales price for a particular year.  After the outbreak of the new crown epidemic, the State Council’s joint defense and control mechanism mentioned in a meeting that rapiravir was selected to conduct research on new coronary pneumonia.On February 15, 2020, Hisun Pharmaceutical received the “Drug Registration Approval” of Fapiravir tablets approved by the State Drug Administration. The dosage form of the product is tablets, and the indication is for the treatment of new or re-popular adultsInfluenza (only used when other anti-influenza virus drugs are not effective or have poor effects).  The State Food and Drug Administration also opened an emergency approval channel for fapiravir, and emergency approval of fapiravir for clinical trials.The indication is a new coronavirus pneumonia.  According to the announcement of Hisun Pharmaceutical, as of now, the company has invested about RMB 40.03 million in the research and development project of piravir.  According to the announcement of Hisun Pharmaceutical, the company expects R & D expenses in 2018 and the first half of 2019 to be 6, respectively.3.9 billion yuan, 1.9.3 billion yuan.  According to Hisun Pharmaceutical’s announcement, the company’s proposed 2019 net profit attributable to shareholders of listed companies is 80 million to 105 million yuan.  Obviously, due to the impairment of a large amount of historical R & D investment assets, Hisun ‘s performance profit is mainly due to the sale of assets.  Hisun Pharmaceutical said that the company’s earnings forecast was mainly due to the company’s completion of the equity exchange transaction of its subsidiary Zhejiang Hisun Borui Bio-Pharmaceutical Co., Ltd. and other non-core long-term asset disposals.US $ 900 million, after excluding the above non-recurring gains and losses, the company’s 2019 annual budget replaced 25.100 million to 24.8.5 billion yuan.Reporter Li Yunqi edited Sun Yong proofreading Chen Diyan